ARDANA ANNOUNCES GERMAN LAUNCH OF STRIANT™ SR THROUGH CYTOCHEMIA AG

Edinburgh, UK, 5th October 2005;  Ardana plc (LSE:ARA), t announces that its partner, Cytochemia AG, has commenced marketing of Striant™SR, Ardana’s testosterone replacement therapy for male hypogonadism, in Germany.

The German launch of Striant™SR was announced at the 57th Congress of the German Society of Urology meeting in Düsseldorf, which was attended by approximately 3,000 urologists. Striant™SR is now available on prescription in Germany which, with an estimated size of €15.2 million per annum*, is the largest market for testosterone replacement therapies in Europe.  Cytochemia AG will target all 3,500 urologists plus andrologists in the country.

This follows the announcement of Ardana’s German sales and marketing agreement with Cytochemia on Striant™SR on 16th June 2005. Financial terms of the German distribution partnership were not disclosed but Ardana received an upfront payment and will have ongoing revenues for the supply of Striant™SR to Cytochemia.

In addition, Ardana also announces today that Mode Medical has been appointed sales and marketing agent, responsible for promoting Striant™SR to endocrinology consultants in Ireland. With an estimated size of €0.25 million and a growth rate of 42% per annum, the Irish market is small but fast growing.

Striant™SR is a mucoadhesive buccal (gum surface) tablet containing 30mg of testosterone and is indicated as a replacement therapy for male hypogonadism when deficiency of testosterone has been confirmed. Striant™SR is the first-to-market buccal adhesive tablet and is marketed by Ardana’s own sales force in the UK, to urologists and endocrinologists. Other therapies for male hypogonadism include injectable formulations of testosterone, oral preparations, transdermal patches, topical gels and sub-cutaneous implants.

Dr. Maureen Lindsay, Chief Executive of Ardana, said:

“Today’s announcement demonstrates Ardana’s commitment to expand in key European markets and underlines its determination to introduce novel therapies for indications where there are unmet patient needs. “

*Source: MAT June 2005, IMS data

For more information contact:

back to top